Verastem Oncology (VSTM) has announced its early exercise of the option to license VS-7375 from GenFleet Therapeutics. This compound is a promising oral and selective inhibitor targeting the KRAS G12D mutation. Additionally, Verastem unveiled initial clinical data from GenFleet's ongoing Phase 1 trial in China, which is still enrolling participants for its dose-escalation study.
Dan Paterson, CEO of Verastem Oncology, commented on this strategic move, stating that the decision to secure the license early was driven by favorable safety, pharmacokinetics, and efficacy results observed thus far in the Phase 1 trial in China. These findings meet expectations and critically show that oral bioavailability is being achieved, with exposures correlating with significant tumor regressions in preclinical models with the KRAS G12D mutation. Paterson highlighted Verastem's eagerness to expand upon GenFleet's groundwork in China by progressing VS-7375 towards clinical trials in the United States by mid-2025.
